eClinical Technology and Industy News

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder

Excerpt from the Press Release:

MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.

“Vanderbilt University has been a tremendous partner for our ATH434 clinical development program, and we are very excited to utilize their expertise as our first U.S. trial site,” said David Stamler, M.D., Chief Executive Officer, Alterity. “ATH434 is a potential disease modifying treatment for individuals living with MSA, a rapidly progressive Parkinsonian disorder with no approved treatment. The opening of enrollment in the U.S. is a major milestone for this trial and we are now actively recruiting patients in three regions: Europe, Asia-Pacific, and the U.S. We expect to add additional sites in the U.S. and Europe over the next few months to increase access to the study.”

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?